As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...

In today’s ACT Brief, we explore how sites are taking the lead on AI adoption to strengthen feasibility and enrollment, why earlier cross-functional alignment is critical in data-driven trials, and ...